These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 15708050

  • 21. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ, Etzioni R, Vessella RL, Hu C, Goodman GE.
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [Abstract] [Full Text] [Related]

  • 26. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C, Roobol MJ, Roemeling S, Schröder FH.
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [Abstract] [Full Text] [Related]

  • 27. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG.
    Cancer; 2004 Apr 01; 100(7):1397-405. PubMed ID: 15042673
    [Abstract] [Full Text] [Related]

  • 28. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK.
    J Urol; 2006 Apr 01; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
    Zhu H, Roehl KA, Antenor JA, Catalona WJ.
    Urology; 2005 Sep 01; 66(3):547-51. PubMed ID: 16140075
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.
    BJU Int; 2012 Dec 01; 110(11):1654-60. PubMed ID: 23043563
    [Abstract] [Full Text] [Related]

  • 34. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ, Zappa M, Määttänen L, Ciatto S.
    Prostate; 2007 Mar 01; 67(4):439-46. PubMed ID: 17192912
    [Abstract] [Full Text] [Related]

  • 35. The value of prostatic specific antigen in prostate cancer screening in the community.
    Jubelirer SJ, Tierney JP, Oliver S, Serrato JM, Farra S, Plymale J, Hodge E.
    W V Med J; 1994 Apr 01; 90(4):140-2. PubMed ID: 7516602
    [Abstract] [Full Text] [Related]

  • 36. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
    Gann PH, Ma J, Catalona WJ, Stampfer MJ.
    J Urol; 2002 Jun 01; 167(6):2427-34. PubMed ID: 11992051
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Pelzer AE, Tewari A, Bektic J, Berger AP, Frauscher F, Bartsch G, Horninger W.
    Urology; 2005 Nov 01; 66(5):1029-33. PubMed ID: 16286118
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.